Harmony Biosciences Holdings, Inc. · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 22.0% margin the price requires -6.6% 3y revenue CAGR against 14.7% consensus, a cushion of +27.2pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Unaffected.
Breaks if: the unexplained 24% drawdown reveals a franchise or patent problem. We re-check this against analyst estimates every evening.
10 years, at a 22% margin analysts expect
+9.7%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
7 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 154% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 22, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits near the middle of the published models, agreeing with the consensus that rapid growth will decelerate, while refusing to pay for the pipeline upside that fuels the bull cases or the steep decline the bear case demands.
Whether the newly designated orexin-2 receptor agonist (BP-205) can deliver enough future revenue to offset the declining Wakix trajectory the price currently assumes — and unit volume data can test this.
What the price refuses to pay for, and the full reconstruction, on the HRMY quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names